Milton Packer

Q: What Schools Are Affiliated With Milton Packer

Milton Packer is affiliated with the following schools: Icahn School of Medicine at Mount Sinai, RWTH Aachen University, London School of Hygiene and Tropical Medicine, Columbia University, Baylor University, University of Texas Southwestern Medical Center, Monash University, Harvard University, University of Oslo, Aarhus University, University of Hull, Imperial College London

Milton Packer's AcademicInfluence.com Rankings

Milton Packer

Biology

#2047

World Rank

#3299

Historical Rank

Physiology

#28

World Rank

#100

Historical Rank

biology Degrees

Milton Packer

Philosophy

#1948

World Rank

#3421

Historical Rank

Logic

#374

World Rank

#720

Historical Rank

philosophy Degrees

Download Badge

Biology
Philosophy

Why Is Milton Packer Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Milton Packer's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Angiotensin-neprilysin inhibition versus enalapril in heart failure. (2014) (4566)
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. (1996) (3965)
Bcl-2 Antiapoptotic Proteins Inhibit Beclin 1-Dependent Autophagy (2005) (3451)
Effect of carvedilol on survival in severe chronic heart failure. (2001) (3027)
Cardiac resynchronization in chronic heart failure. (2002) (2830)
ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. (2002) (2786)
Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. (1990) (2616)
Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. (1991) (2133)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. (2020) (1835)
The Seattle Heart Failure Model: Prediction of Survival in Heart Failure (2006) (1797)
Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial (2003) (1391)
Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study (2002) (1260)
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. (1999) (1141)
Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) (2004) (1127)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction. (2021) (1081)
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. (2019) (1066)
The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. (1992) (1020)
Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis (2012) (980)
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial (2012) (972)
Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. (2007) (939)
Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. (1996) (931)
Sex differences in the management of coronary artery disease. Survival and Ventricular Enlargement Investigators. (1991) (767)
Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. (1993) (750)
Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). (1995) (684)
Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. (1996) (667)
Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) (2002) (630)
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials (2020) (599)
Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. (1998) (599)
Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. (2014) (570)
Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group. (1988) (567)
Double-Blind, Placebo-Controlled Study of the Effects of Carvedilol in Patients With Moderate to Severe Heart Failure (1996) (555)
Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure (2015) (554)
Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. (1986) (551)
Neurohormonal interactions and adaptations in congestive heart failure. (1988) (547)
Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. (2004) (524)
Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia. (1984) (426)
Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group. (1989) (416)
Proportionate and Disproportionate Functional Mitral Regurgitation: A New Conceptual Framework That Reconciles the Results of the MITRA-FR and COAPT Trials. (2019) (403)
Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. (2001) (398)
Consensus recommendations for the management of chronic heart failure: Introduction (1999) (391)
Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. (2013) (379)
Sudden unexpected death in patients with congestive heart failure: a second frontier. (1985) (378)
Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials (2018) (372)
Prevention and reversal of nitrate tolerance in patients with congestive heart failure. (1987) (370)
Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. (1989) (362)
Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. (1994) (348)
Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. (2000) (344)
Diuretic resistance predicts mortality in patients with advanced heart failure. (2002) (338)
Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. (2015) (335)
Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. (1996) (310)
Prognostic Impact of Plasma N-Terminal Pro–Brain Natriuretic Peptide in Severe Chronic Congestive Heart Failure: A Substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial (2004) (306)
Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. (1994) (296)
Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. (2001) (286)
Comparison of captopril and enalapril in patients with severe chronic heart failure. (1986) (285)
Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium. (2018) (284)
Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. (2003) (279)
Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action (2017) (276)
Development of autophagy inducers in clinical medicine. (2015) (275)
Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. (2005) (268)
Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials (2020) (267)
N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. (1994) (260)
Hemodynamic and Clinical Tachyphylaxisc to Prazosin-Mediated Afterload Reductionin Severe Chronic Congestive Heart Failure (1979) (256)
Heart failure with a normal ejection fraction: is it really a disorder of diastolic function? (2003) (253)
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. (2017) (252)
Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. (2016) (251)
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure (2019) (250)
Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure (2017) (248)
Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. (2018) (241)
Pathophysiology of chronic heart failure (1992) (235)
Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. (1984) (234)
Utilization of Hepatocellular Carcinoma Surveillance Among American Patients: A Systematic Review (2012) (233)
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. (2017) (224)
Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction (2016) (217)
Declining Risk of Sudden Death in Heart Failure (2017) (216)
Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. (1987) (215)
Safety and efficacy of carvedilol in severe heart failure (1997) (215)
Abnormalities of diastolic function as a potential cause of exercise intolerance in chronic heart failure. (1990) (212)
Deleterious effects of hydralazine in patients with pulmonary hypertension. (1982) (208)
Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. (1987) (205)
Can physicians always explain the results of clinical trials? A case study of amlodipine in heart failure. (1999) (202)
Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. (2000) (201)
Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. (1985) (197)
Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. (2001) (194)
Impaired left atrial function in heart failure with preserved ejection fraction (2014) (194)
Utility of impedance cardiography for the identification of short-term risk of clinical decompensation in stable patients with chronic heart failure. (2006) (193)
Chronic Kidney Disease, Cardiovascular Risk, and Response to Angiotensin-Converting Enzyme Inhibition After Myocardial Infarction: The Survival And Ventricular Enlargement (SAVE) Study (2004) (193)
Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension (2015) (192)
Left heart failure with a normal ejection fraction: identification of different pathophysiologic mechanisms. (2005) (192)
Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. (1999) (192)
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF (2015) (182)
Heart failure in the 1990s: evolution of a major public health problem in cardiovascular medicine. (1993) (177)
Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure. (1995) (176)
Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial (2019) (175)
Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. (2017) (174)
Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. (1996) (172)
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial (2016) (171)
Activation of neurohumoral systems in postinfarction left ventricular dysfunction. (1993) (166)
Sex‐specific cardiovascular structure and function in heart failure with preserved ejection fraction (2014) (163)
Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. (2000) (160)
Cardiovascular drug development: is it dead or just hibernating? (2015) (159)
Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction (2015) (157)
Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) (2014) (153)
Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure (2017) (152)
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF (2017) (152)
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status (2020) (150)
Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. (2004) (149)
How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. (1993) (147)
Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure? (1995) (147)
Health-Related Quality of Life Outcomes in PARADIGM-HF (2015) (146)
Hemodynamic Consequences of Combined Beta‐adrenergic and Slow Calcium Channel Blockade in Man (1982) (143)
Lack of relation between ventricular arrhythmias and sudden death in patients with chronic heart failure. (1992) (143)
Hemodynamic changes mimicking a vasodilator drug response in the absence of drug therapy after right heart catheterization in patients with chronic heart failure. (1985) (142)
Hemodynamic patterns of response during long-term captopril therapy for severe chronic heart failure. (1983) (138)
Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction (2019) (138)
Associations of gender and etiology with outcomes in heart failure with systolic dysfunction: a pooled analysis of 5 randomized control trials. (2007) (136)
Vasodilator and inotropic therapy for severe chronic heart failure: passion and skepticism. (1983) (135)
Selection Bias in the Use of Thrombolytic Therapy in Acute Myocardial Infarction (1991) (133)
Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial (2017) (130)
Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF. (2019) (129)
Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial (2019) (129)
Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. (2004) (129)
Pathophysiological Mechanisms Underlying the Adverse Effects of Calcium Channel‐Blocking Drugs in Patients With Chronic Heart Failure (1989) (128)
Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity (2018) (127)
Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure (1993) (127)
Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. (2015) (124)
Vasodilator therapy for primary pulmonary hypertension. Limitations and hazards. (1985) (123)
SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action (2020) (122)
Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure? (2003) (121)
Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. (2019) (121)
Rebound hemodynamic events after the abrupt withdrawal of nitroprusside in patients with severe chronic heart failure. (1979) (120)
Prognostic importance of the serum magnesium concentration in patients with congestive heart failure. (1990) (118)
Calcium channel blockers in chronic heart failure. The risks of "physiologically rational" therapy. (1990) (116)
B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. (2019) (115)
Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. (2018) (115)
The development of positive inotropic agents for chronic heart failure: how have we gone astray? (1993) (114)
Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. (2016) (114)
Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial. (2016) (113)
The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. (2004) (113)
Correction of dilutional hyponatremia in severe chronic heart failure by converting-enzyme inhibition. (1984) (111)
Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope. (1988) (111)
Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). (2016) (110)
Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial (2018) (110)
Can Further Benefit Be Achieved by Adding Flosequinan to Patients With Congestive Heart Failure Who Remain Symptomatic on Diuretic, Digoxin, and an Angiotensin Converting Enzyme Inhibitor? Results of the Flosequinan‐ACE Inhibitor Trial (FACET) (1993) (110)
Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2. (2018) (109)
How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction? A Redefinition of Evidence-Based Medicine. (2020) (109)
Activation of neurohumoral systems following acute myocardial infarction. (1991) (108)
Relation between serum sodium concentration and the hemodynamic and clinical responses to converting enzyme inhibition with captopril in severe heart failure. (1984) (108)
Randomized,multicenter,double-blind,placebo-controlled evaluation of amlodipine in patients with mild-to-moderate heart failure (1991) (107)
Geographic variations in the PARADIGM-HF heart failure trial (2016) (106)
Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM‐HF trial (2019) (106)
Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. (2016) (105)
Drug therapy. Combined beta-adrenergic and calcium-entry blockade in angina pectoris. (1989) (104)
Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. (1998) (100)
Determinants of Drug Response in Severe Chronic Heart Failure. 1. Activation of Vasoconstrictor Forces During Vasodilator Therapy (1981) (100)
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction (2020) (98)
Dose requirements of hydralazine in patients with severe chronic congestive heart failure. (1980) (97)
Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis (2016) (95)
Role of endothelin in the exercise intolerance of chronic heart failure. (1995) (95)
Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction. (2017) (94)
Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure. (1996) (94)
MULTICENTER, DOUBLEBLIND PLACEBO CONTROLLED STUDY OF LONG TERMENDOTHELIN BLOCKADE WITH BOSENTAN IN CHRONIC HEART FAILURE RESULTS OF THE REACH-1 TRIAL. ABSTRACT (1998) (93)
Preservation of glomerular filtration rate in human heart failure by activation of the renin-angiotensin system. (1986) (93)
Importance of left ventricular chamber size in determining the response to hydralazine in severe chronic heart failure. (1980) (93)
How should we judge the efficacy of drug therapy in patients with chronic congestive heart failure? The insights of six blind men. (1987) (93)
NT‐proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT‐proBNP substudy (2004) (93)
Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease. (1984) (92)
Hemodynamic characterization of tolerance to long-term hydralazine therapy in severe chronic heart failure. (1982) (92)
Sudden death in heart failure: vascular or electrical? (1999) (91)
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure (2014) (91)
Immediate and long-term pathophysiologic mechanisms underlying the genesis of sudden cardiac death in patients with congestive heart failure. (1987) (90)
Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? (1996) (89)
Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. (2015) (88)
Calcium-channel blockade in the management of severe chronic congestive heart failure: a bridge too far. (1987) (88)
Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials. (2017) (87)
Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial (2018) (87)
The search for the ideal positive inotropic agent. (1993) (87)
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function (2020) (87)
Decreased BECN1 mRNA Expression in Human Breast Cancer is Associated With Estrogen Receptor-Negative Subtypes and Poor Prognosis (2015) (87)
Indications for left ventricular aneurysmectomy. (1983) (85)
Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. (1987) (85)
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial (2021) (83)
Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy (2016) (83)
Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF Trial. (2016) (83)
Revive Ii: Multicenter Placebo-controlled Trial of Levosimendan on Clinical Status in Acutely Decompensated Heart Failure (2005) (83)
Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure. (1997) (83)
Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial (2014) (82)
Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study. (1993) (82)
Elevation in High-Sensitivity Troponin T in Heart Failure and Preserved Ejection Fraction and Influence of Treatment With the Angiotensin Receptor Neprilysin Inhibitor LCZ696 (2014) (82)
Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). (2013) (81)
HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches. Heart Failure Society of America. (2000) (81)
Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. (2001) (79)
Dementia‐related adverse events in PARADIGM‐HF and other trials in heart failure with reduced ejection fraction (2016) (79)
Survival in congestive heart failure during treatment with drugs with positive inotropic actions. (1987) (78)
Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. (2014) (78)
New Evidence Supporting a Novel Conceptual Framework for Distinguishing Proportionate and Disproportionate Functional Mitral Regurgitation. (2020) (77)
Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction. (1987) (77)
Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF. (2019) (77)
Do sodium‐glucose co‐transporter‐2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis (2018) (75)
Characterization of the inflammatory‐metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease (2020) (74)
Clinical relevance of verapamil plasma levels in stable angina pectoris. (1982) (74)
Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure. (1995) (72)
Physiologic and pharmacologic determinants of vasodilator response: a conceptual framework for rational drug therapy for chronic heart failure. (1982) (72)
Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared with Valsartan in HFpEF. (2019) (72)
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial (2021) (71)
Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency (2016) (71)
Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced. (2021) (71)
Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. (2019) (70)
Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group. (2001) (70)
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial (2020) (70)
Heart Failure: The Most Important, Preventable, and Treatable Cardiovascular Complication of Type 2 Diabetes (2017) (70)
Effect of beta‐adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial (2017) (66)
Mechanisms Leading to Differential Hypoxia Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics. (2020) (66)
Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake. (2020) (65)
Do β-blockers prolong survival in heart failure only by inhibiting the β1-receptor? A perspective on the results of the COMET trial (2003) (65)
Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction (2020) (64)
What causes tolerance to nitroglycerin? The 100 year old mystery continues. (1990) (64)
Correction to: Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. (2021) (64)
Comparative hemodynamic effects of procainamide, tocainide, and encainide in severe chronic heart failure. (1990) (64)
Interaction of prostaglandins and angiotensin II in the modulation of renal function in congestive heart failure (1988) (63)
Hormone-electrolyte interactions in the pathogenesis of lethal cardiac arrhythmias in patients with congestive heart failure. Basis of a new physiologic approach to control of arrhythmia. (1986) (63)
What causes sudden death in patients with chronic heart failure and a reduced ejection fraction? (2019) (63)
Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF) (2018) (63)
Current role of beta-adrenergic blockers in the management of chronic heart failure. (2001) (63)
Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors (2020) (62)
Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. (2014) (62)
Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial (2016) (62)
Role of Impaired Nutrient and Oxygen Deprivation Signaling and Deficient Autophagic Flux in Diabetic CKD Development: Implications for Understanding the Effects of Sodium-Glucose Cotransporter 2-Inhibitors. (2020) (62)
The erythrocyte sedimentation rate in congestive heart failure. (1991) (62)
Income Inequality and Outcomes in Heart Failure: A Global Between-Country Analysis. (2019) (62)
Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium–glucose cotransporter 2 inhibitors (2020) (61)
Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) (2018) (60)
Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure. (1989) (60)
Rapid evidence‐based sequencing of foundational drugs for heart failure and a reduced ejection fraction (2021) (59)
Physical training alters the pathogenesis of pacing-induced heart failure through endothelium-mediated mechanisms in awake dogs. (1997) (59)
Quantification of valve regurgitation by radionuclide angiography before and after valve replacement surgery. (1981) (59)
Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes (2019) (59)
Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. (1997) (58)
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. (2021) (58)
Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. (2001) (58)
The prevalence and importance of frailty in heart failure with reduced ejection fraction – an analysis of PARADIGM‐HF and ATMOSPHERE (2020) (58)
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction (2021) (57)
Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE 1 study (2003) (56)
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial (2021) (56)
Worsening Heart Failure During the Use of DPP-4 Inhibitors: Pathophysiological Mechanisms, Clinical Risks, and Potential Influence of Concomitant Antidiabetic Medications. (2018) (56)
End of the oldest controversy in medicine. Are we ready to conclude the debate on digitalis? (1997) (55)
Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients with Heart Failure and Reduced Ejection Fraction:PARADIGM-HF. (2019) (55)
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. (2020) (54)
Hemodynamic effects of BTS 49465, a new long-acting systemic vasodilator drug, in patients with severe congestive heart failure. (1987) (54)
Circadian rhythm and sudden death in heart failure: results from Prospective Randomized Amlodipine Survival Trial. (2000) (54)
Neprilysin inhibition for heart failure. (2014) (54)
Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis. (2020) (53)
Interdependence of Atrial Fibrillation and Heart Failure With a Preserved Ejection Fraction Reflects a Common Underlying Atrial and Ventricular Myopathy (2020) (53)
Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) (2020) (53)
The impossible task of developing a new treatment for heart failure. (2002) (52)
Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure. (1986) (52)
Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs (2020) (51)
Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. (2000) (51)
Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction (2020) (51)
Can brain natriuretic peptide be used to guide the management of patients with heart failure and a preserved ejection fraction? The wrong way to identify new treatments for a nonexistent disease. (2011) (50)
Empagliflozin and Major Renal Outcomes in Heart Failure. (2021) (50)
Relation between exercise-induced changes in ejection fraction and systolic loading conditions at rest in aortic regurgitation. (1984) (50)
Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection FractionCLINICAL PERSPECTIVE (2016) (49)
The prognostic value of troponin T and N‐terminal pro B‐type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes (2018) (48)
Coronary endothelial dysfunction precedes heart failure and reduction of coronary reserve in awake dogs. (1997) (48)
Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy (2017) (48)
Effects of levosimendan on myocardial contractility and oxygen consumption. (1996) (48)
Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation (2017) (47)
Do DPP-4 Inhibitors Cause Heart Failure Events by Promoting Adrenergically Mediated Cardiotoxicity?: Clues From Laboratory Models and Clinical Trials (2018) (47)
Therapeutic options in the management of chronic heart failure. Is there a drug of first choice? (1989) (47)
Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition. (1987) (46)
Adverse effects of converting-enzyme inhibition in patients with severe congestive heart failure: pathophysiology and management. (1986) (46)
Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure (2017) (46)
Growth differentiation factor‐15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM‐HF trial (2018) (46)
New concepts in the pathophysiology of heart failure: beneficial and deleterious interaction of endogenous haemodynamic and neurohormonal mechanisms (1996) (46)
Treatment of chronic heart failure (1992) (46)
Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion (2019) (46)
Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan. (2000) (45)
Pathophysiological mechanisms underlying the effects of beta-adrenergic agonists and antagonists on functional capacity and survival in chronic heart failure. (1990) (45)
Hemodynamic factors limiting the response to transdermal nitroglycerin in severe chronic congestive heart failure (1986) (45)
Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure. (1991) (45)
Potential role of potassium as a determinant of morbidity and mortality in patients with systemic hypertension and congestive heart failure. (1990) (44)
Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study. (2005) (44)
Contrasting Effects of Pharmacological, Procedural and Surgical Interventions on Proportionate and Disproportionate Functional Mitral Regurgitation in Chronic Heart Failure. (2019) (44)
Hemodynamic and clinical effects of combined verapamil and propranolol therapy in angina pectoris. (1982) (44)
Redefining Heart Failure With a Reduced Ejection Fraction. (2019) (43)
Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events. (2019) (43)
Role of surrogate end points in the evaluation of drugs for heart failure. (1993) (43)
Therapeutic application of calcium-channel antagonists for pulmonary hypertension. (1985) (42)
Prolonging life in patients with congestive heart failure: the next frontier. Introduction. (1987) (42)
Effects of beta-adrenergic blockade on survival of patients with chronic heart failure. (1997) (42)
Critical Examination of Mechanisms Underlying the Reduction in Heart Failure Events With SGLT2 Inhibitors: Identification of a Molecular Link Between Their Actions to Stimulate Erythrocytosis and to Alleviate Cellular Stress. (2020) (42)
Cobalt Cardiomyopathy: A Critical Reappraisal in Light of a Recent Resurgence (2016) (42)
Oral vasodilator therapy for chronic heart failure: a plea for caution. (1978) (42)
Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. (2020) (41)
Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure. (2018) (40)
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials (2022) (40)
Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study. (1993) (40)
Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators. (1998) (40)
Characterization, Pathogenesis, and Clinical Implications of Inflammation‐Related Atrial Myopathy as an Important Cause of Atrial Fibrillation (2020) (40)
Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. (2006) (40)
Role of Deranged Energy Deprivation Signaling in the Pathogenesis of Cardiac and Renal Disease in States of Perceived Nutrient Overabundance. (2020) (40)
Usefulness of plasma renin activity in predicting haemodynamic and clinical responses and survival during long term converting enzyme inhibition in severe chronic heart failure. Experience in 100 consecutive patients. (1985) (40)
Beta-blockade in heart failure. Basic concepts and clinical results. (1998) (40)
Comparative hemodynamic and clinical effects of long-term treatment with prazosin and captopril for severe chronic congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy. (1986) (39)
Detrimental effects of verapamil in patients with primary pulmonary hypertension. (1984) (39)
Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure. (1986) (39)
Congestive heart failure: Current controversies and future prospects (1990) (39)
Patients with mild heart failure worsen during withdrawal from digoxin therapy. (1997) (38)
Interplay of adenosine monophosphate‐activated protein kinase/sirtuin‐1 activation and sodium influx inhibition mediates the renal benefits of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: A novel conceptual framework (2020) (37)
Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impa (2018) (37)
Effect of carvedilol in severe chronic heart failure (1996) (37)
Effect of catheter ablation on pre-existing abnormalities of left atrial systolic, diastolic, and neurohormonal functions in patients with chronic heart failure and atrial fibrillation (2019) (37)
Importance of Clinical Worsening of Heart Failure Treated in the Outpatient SettingCLINICAL PERSPECTIVE (2016) (36)
The placebo effect in heart failure. (1990) (36)
Mutual Antagonism of Hypoxia-Inducible Factor Isoforms in Cardiac, Vascular, and Renal Disorders (2020) (36)
Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment (2019) (36)
Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas (2018) (36)
The epicardial adipose inflammatory triad: coronary atherosclerosis, atrial fibrillation, and heart failure with a preserved ejection fraction (2018) (36)
Efficacy of captopril in low-renin congestive heart failure: importance of sustained reactive hyperreninemia in distinguishing responders from nonresponders. (1984) (35)
Role of the sympathetic nervous system in chronic heart failure. A historical and philosophical perspective. (1990) (35)
Rationale for and design of the TRUE‐AHF trial: the effects of ularitide on the short‐term clinical course and long‐term mortality of patients with acute heart failure (2017) (35)
Clinical and regulatory implications of the Cardiac Arrhythmia Suppression Trial. (1990) (35)
Derangements in adrenergic–adipokine signalling establish a neurohormonal basis for obesity‐related heart failure with a preserved ejection fraction (2018) (35)
Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the PROFILE Trial After 24 Years. (2017) (34)
Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM‐HF (2017) (34)
Disease–treatment interactions in the management of patients with obesity and diabetes who have atrial fibrillation: the potential mediating influence of epicardial adipose tissue (2019) (34)
Are Meta-Analyses a Form of Medical Fake News?: Thoughts About How They Should Contribute to Medical Science and Practice (2017) (33)
Influence of renal function on the hemodynamic and clinical responses to long-term captopril therapy in severe chronic heart failure. (1986) (33)
A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction (2020) (33)
Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines (2018) (33)
New perspectives on therapeutic application of nitrates as vasodilator agents for severe chronic heart failure. (1983) (33)
Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial (2018) (32)
Digoxin Discontinuation and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. (2019) (32)
Provocation of myocardial ischemic events during initiation of vasodilator therapy for severe chronic heart failure. Clinical and hemodynamic evaluation of 52 consecutive patients with ischemic cardiomyopathy. (1981) (32)
Guideline‐directed medical therapy for heart failure does not exist: a non‐judgmental framework for describing the level of adherence to evidence‐based drug treatments for patients with a reduced ejection fraction (2020) (32)
Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. (2021) (32)
Cardiac troponin I, a possible predictor of survival in patients with stable congestive heart failure. (2005) (32)
Adverse hemodynamic and clinical effects of encainide in severe chronic heart failure. (1989) (31)
Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. (2019) (31)
Comparative effects of captopril and isosorbide dinitrate on pulmonary arteriolar resistance and right ventricular function in patients with severe left ventricular failure: results of a randomized crossover study. (1985) (31)
Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition. (1987) (31)
Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan. (2002) (31)
The effects of sacubitril/valsartan on coronary outcomes in PARADIGM‐HF (2017) (31)
Hemodynamic responses to combined therapy with captopril and hydralazine in patients with severe heart failure. (1983) (31)
Part I: pharmacologic and hemodynamic actions and interactions. Pharmacologic and hemodynamic mechanisms underlying the antianginal actions of verapamil. (1982) (30)
Long-term effectiveness of verapamil in stable and unstable angina pectoris. One-year follow-up of patients treated in placebo-controlled double-blind randomized clinical trials. (1982) (30)
IGFBP7 (Insulin-Like Growth Factor–Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure (2018) (30)
Kicking the tyres of a heart failure trial: physician response to the approval of sacubitril/valsartan in the USA (2016) (30)
Influence of diabetes mellitus on changes in left ventricular performance and renal function produced by converting enzyme inhibition in patients with severe chronic heart failure. (1987) (30)
Differential Pathophysiological Mechanisms in Heart Failure With a Reduced or Preserved Ejection Fraction in Diabetes. (2021) (30)
Uric Acid Is a Biomarker of Oxidative Stress in the Failing Heart: Lessons Learned from Trials With Allopurinol and SGLT2 Inhibitors. (2020) (30)
Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial. (2021) (30)
Do vasodilators prolong life in heart failure? (1987) (29)
Serum potassium in the PARADIGM‐HF trial (2020) (28)
Converting-enzyme inhibition for severe chronic heart failure: views from a skeptic. (1985) (28)
Hemodynamic and clinical significance of the pulmonary vascular response to long-term captopril therapy in patients with severe chronic heart failure. (1985) (28)
HFSA guidelines for the management of patients with heart failure due to left ventricular systolic dysfunction--pharmacological approaches. (2000) (28)
Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure: A 20-Year Perspective (2016) (28)
Cumulative Hemodynamic Response to Short‐Term Treatment with Flosequinan (BTS 49465), a New Direct‐Acting Vasodilator Drug, in Severe Chronic Congestive Heart Failure (1988) (27)
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction (2021) (27)
The use of placebo controls. (1995) (27)
Comparative effects of low dose versus high-dose lisinopril on survival and major events in chronic heart failure : the Assessment of Treatment with Lisinopril And Survival Study (ATLAS) (1998) (27)
Contrasting hemodynamic responses in severe heart failure: comparison of captopril and other vasodilator drugs. (1982) (27)
Hemodynamic evaluation of hydralazine dosage in refractory heart failure (1980) (27)
Differences in hemodynamic effects of nitroprusside and prazosin in severe chronic congestive heart failure: evidence for a direct negative chronotropic effect of prazosin. (1979) (25)
Longevity genes, cardiac ageing, and the pathogenesis of cardiomyopathy: implications for understanding the effects of current and future treatments for heart failure (2020) (25)
Impact of exercise training on ventricular properties in a canine model of congestive heart failure. (1997) (25)
Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction (2020) (25)
Beta-blockade in the management of chronic heart failure. Another step in the conceptual evolution of a neurohormonal model of the disease. (1996) (25)
Prognostic benefit of beta-blockers in patients not receiving ACE-Inhibitors. (2005) (24)
Is it ethical to administer vasodilator drugs to patients with primary pulmonary hypertension? (1989) (24)
Love of Angiotensin-Converting Enzyme Inhibitors in the Time of Cholera. (2016) (24)
A device is not a drug. (2003) (24)
Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction in Patients With Nonalcoholic Fatty Liver Disease. (2020) (24)
Augmentation of glucagon‐like peptide‐1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure (2018) (24)
Is Activation of the Sympathetic Nervous System Beneficial or Detrimental to the Patient with Chronic Heart Failure? Lessons Learned from Clinical Trials with β‐Adrenergic Agonists and Antagonists (1989) (24)
Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial. (2003) (24)
The conundrum of patients with obesity, exercise intolerance, elevated ventricular filling pressures and a measured ejection fraction in the normal range (2019) (23)
Hemodynamic factors limiting the response to transdermal nitroglycerin in severe chronic congestive heart failure. (1987) (23)
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction: A Phase II Randomised-Controlled Trial (2012) (23)
Effect of Empagliflozin on Cardiovascular and Kidney Outcomes in Patients with Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial (2021) (23)
Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme (2022) (23)
SacubitrilValsartan in Heart Failure: Why Are More Physicians Not Prescribing It? (2016) (22)
Verapamil therapy for stable and unstable angina pectoris: calcium channel antagonists in perspective. (1982) (22)
Nitroglycerin therapy in the management of pulmonary hypertensive disorders. (1984) (22)
Quantitative differences in the hemodynamic effects of captopril and nitroprusside in severe chronic heart failure. (1983) (22)
Is metformin beneficial for heart failure in patients with type 2 diabetes? (2017) (21)
Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial (2021) (21)
Building Castles in the Sky. (2018) (21)
Conceptual dilemmas in the classification of vasodilator drugs for severe chronic heart failure. Advocacy of a pragmatic approach to the selection of a therapeutic agent. (1984) (21)
Epicardial fat in heart failure with reduced versus preserved ejection fraction (2021) (21)
Systemic vasoconstrictor effects of oxygen administration in obliterative pulmonary vascular disorders. (1986) (21)
Unbelievable Folly of Clinical Trials in Heart Failure: The Inconvenient Truth About How Investigators and Guidelines Weigh Evidence. (2016) (20)
Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction (2019) (20)
Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction. (2022) (20)
Long-term, open-label experience with an endothelin receptor antagonist, Bosentan, in patients with severe chronic heart failure (1999) (20)
Study design of a mortality trial with intravenous levosimendan - the SURVIVE study - in patients with acutely decompensated heart failure (2004) (20)
Totality of evidence in trials of sodium–glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice (2020) (20)
Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. (2004) (20)
Second generation calcium channel blockers in the treatment of chronic heart failure: are they any better than their predecessors? (1989) (20)
Long-term strategies in the management of heart failure: looking beyond ventricular function and symptoms. (1992) (20)
Effects of oral milrinone on mortality in severe chronic heart failure. Commentary (1992) (20)
The Alchemist’s Nightmare: Might Mesenchymal Stem Cells That Are Recruited to Repair the Injured Heart Be Transformed Into Fibroblasts Rather Than Cardiomyocytes? (2018) (19)
Incidence and Outcomes of Pneumonia in Patients With Heart Failure. (2021) (19)
Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failure. (1984) (19)
Heart Failure With a Mid-Range Ejection Fraction: A Disorder That a Psychiatrist Would Love. (2017) (19)
Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial (2021) (19)
Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial. (2021) (19)
Molecular, Cellular, and Clinical Evidence That Sodium‐Glucose Cotransporter 2 Inhibitors Act as Neurohormonal Antagonists When Used for the Treatment of Chronic Heart Failure (2020) (19)
Lack of Bioequivalence between Different Formulations of Isosorbide Dinitrate and Hydralazine and the Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine (2007) (18)
Drugs That Ameliorate Epicardial Adipose Tissue Inflammation May Have Discordant Effects in Heart Failure With a Preserved Ejection Fraction as Compared With a Reduced Ejection Fraction (2019) (18)
Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis (2022) (18)
Role of ketogenic starvation sensors in mediating the renal protective effects of SGLT2 inhibitors in type 2 diabetes. (2020) (18)
Interplay of AMPK/SIRT1 Activation and Sodium Influx Inhibition Mediates the Renal Benefits of SGLT2 Inhibitors in Type 2 Diabetes: a Novel Conceptual Framework. (2020) (18)
Angiotensin Neprilysin Inhibition for Patients With Heart Failure: What If Sacubitril/Valsartan Were a Treatment for Cancer? (2016) (18)
Do beta-blockers prolong survival in chronic heart failure? A review of the experimental and clinical evidence. (1998) (17)
PARADIGM-HF--the experts' discussion. (2014) (17)
Early Effects of Starting Doses of Enalapril in Patients with Chronic Heart Failure in the SOLVD Treatment Trial. (2020) (17)
Is the renin-angiotensin system really unnecessary in patients with severe chronic heart failure: The price we pay for interfering with evolution* (1985) (17)
Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR‐Preserved trial (2021) (17)
Dose dependence of the hemodynamic responses to nitrate therapy in patients with refractory congestive heart failure (1979) (17)
Mechanisms of nitrate action in patients with severe left ventricular failure: conceptual problems with the theory of venosequestration. (1985) (17)
Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study (1999) (17)
How Should Physicians Assess Myocardial Contraction?: Redefining Heart Failure With a Preserved Ejection Fraction. (2020) (17)
Potentiation of Insulin Signaling Contributes to Heart Failure in Type 2 Diabetes (2018) (17)
Current perspectives on the design of phase II trials of new drugs for the treatment of heart failure. (2000) (16)
Prognostic importance of the oxidized product of catecholamines, adrenolutin, in patients with severe heart failure. (2003) (16)
Concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR‐Reduced trial (2021) (16)
Effect of Bosentan and Sildenafil Combination Therapy on Morbidity and Mortality in Pulmonary Arterial Hypertension (PAH): Results From the COMPASS-2 Study (2014) (16)
Prediction of Survival in Heart Failure (2006) (16)
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial (2021) (16)
Neurohormonal and Transcatheter Repair Strategies for Proportionate and Disproportionate Functional Mitral Regurgitation in Heart Failure. (2019) (16)
Identification of Risk Factors Predisposing to the Development of Functional Renal Insufficiency during Treatment with Converting-Enzyme Inhibitors in Chronic Heart Failure1 (1989) (16)
Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors. (1993) (15)
Are the effects of drugs to prevent and to treat heart failure always concordant? The statin paradox and its implications for understanding the actions of antidiabetic medications (2018) (14)
Deleterious hemodynamic effects of lidocaine in severe congestive heart failure. (1989) (14)
Effect of sacubitril/valsartan on investigator‐reported ventricular arrhythmias in PARADIGM‐HF (2021) (14)
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. (2021) (14)
Dose dependent reduction in right and left ventricular filling pressures with hydralazine (1978) (14)
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. (2021) (14)
Hemodynamic consequences of antiarrhythmic drug therapy in patietns with chronic heart failure (1991) (14)
Acute Heart Failure Is an Event Rather Than a Disease: Plea for a Radical Change in Thinking and in Therapeutic Drug Development. (2018) (14)
Clinical predictors of worsening heart failure during withdrawal from digoxin therapy. (1998) (14)
Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. (2019) (14)
Heart Failure and a Preserved Ejection Fraction (2021) (13)
Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled (2022) (13)
Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes (2022) (13)
Design of a prospective patient‐level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure (2020) (13)
Epicardial Adipose Tissue Inflammation Can Cause the Distinctive Pattern of Cardiovascular Disorders Seen in Psoriasis. (2020) (13)
Will long‐acting glucagon‐like peptide‐1 analogues recapitulate our agonizing experience with cyclic AMP‐dependent positive inotropic agents in heart failure? (2018) (13)
Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care (2020) (13)
HFpEF Is the Substrate for Stroke in Obesity and Diabetes Independent of Atrial Fibrillation. (2019) (13)
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial (2022) (13)
Carvedilol reduces the costs of medical care in severe heart failure: an economic analysis of the COPERNICUS study applied to the United Kingdom. (2005) (13)
Vasopressor Response to Angiotensin II Infusion in Patients With Chronic Heart Failure Receiving &bgr;-Blockers (2003) (13)
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 is Effective Across the Spectrum of Ejection Fraction in Heart Failure With Reduced Ejection Fraction (2015) (13)
Why Are Physicians So Confused about Acute Heart Failure? (2019) (13)
Disproportionate functional mitral regurgitation: a new therapeutic target in patients with heart failure and a reduced ejection fraction (2020) (12)
Prevalence and incidence of intra‐ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM‐HF and ATMOSPHERE (2020) (12)
Do Drugs That Ameliorate Epicardial Adipose Tissue Inflammation Have Concordant Benefits on Atrial Fibrillation and on Heart Failure with a Preserved Ejection Fraction? (2019) (12)
Does Metformin Interfere With the Cardiovascular Benefits of SGLT2 Inhibitors? Questions About Its Role as the Cornerstone of Diabetes Treatment. (2020) (12)
Adaptive and maladaptive actions of angiotensin II in patients with severe congestive heart failure. (1987) (12)
Is the Way to Someone's Heart Through Their Stomach? The Cardiorenal Paradox of Incretin-Based Hypoglycemic Drugs in Heart Failure. (2017) (12)
P002. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (2021) (12)
Sustained effectiveness of minoxidil in heart failure after development of tolerance to other vasodilator drugs. (1981) (12)
How Many Exercise Tests Are Needed to Minimize The Placebo Effect of Serial Testing In Patients with Chronic Heart Failure (1990) (12)
Impact of Anemia and the Effect of Empagliflozin in HFrEF: findings from EMPEROR-Reduced. (2021) (12)
Role of the sodium‐hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes (2018) (12)
The clinical significance of nitrate tolerance in patients with chronic heart failure. (1989) (12)
Modulation of functional capacity and survival in congestive heart failure. Effects of activation of the sympathetic nervous system. (1988) (12)
Mitigation of the Adverse Consequences of Nutrient Excess on the Kidney: A Unified Hypothesis to Explain the Renoprotective Effects of Sodium-Glucose Cotransporter 2 Inhibitors (2020) (11)
Heart Failure's Dark Secret: Does Anyone Really Care About Optimal Medical Therapy? (2016) (11)
Digoxin Use and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction. (2019) (11)
Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER‐like endpoint definitions (2022) (11)
Are physicians neglecting the risk of heart failure in diabetic patients who are receiving sulfonylureas? Lessons from the TOSCA.IT trial (2018) (11)
Serum potassium and outcomes in heart failure with preserved ejection fraction: a post‐hoc analysis of the PARAGON‐HF trial (2021) (11)
Angiotensin–neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure (2022) (11)
Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction (2021) (11)
Characterizing ventricular mechanics and energetics following repeated coronary microembolization. (1997) (11)
Major reduction in the risk of sudden cardiac death in patients with chronic heart failure with the use of drug and device combinations that favourably affect left ventricular structure (2019) (10)
The Imminent Demise of Cardiovascular Drug Development (2017) (10)
Acute, non-COVID related medical admissions during the first wave of COVID-19: A retrospective comparison of changing patterns of disease (2020) (10)
Rapid hemodynamic tachyphylaxis to prazosin mediated afterload reduction in refractory heart failure (1978) (10)
Hydralazine-induced ischemia without tachycardia: The importance of coronary perfusion pressure gradients (1978) (10)
Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM‐HF (2017) (10)
The Room Where It Happens: A Skeptic's Analysis of the New Heart Failure Guidelines. (2016) (10)
Converting‐Enzyme Inhibition in the Management of Severe Chronic Congestive Heart Failure: Physiologic Concepts (1987) (10)
Albiglutide in patients with type 2 diabetes and heart failure: a post‐hoc analysis from Harmony Outcomes (2022) (10)
Prevention and Reversal of Nitrate Tolerance in Patients with Congestive Heart Failure (1988) (10)
Prognostic value of echocardiographic evaluation of septal function in acute anteroseptal myocardial infarction. (1979) (10)
Association between sST2 Levels and Cardiovascular Outcomes and Effect of Sacubitril/Valsartan on sST2 Levels: Results From the PARADIGM-HF Trial (2016) (9)
Hormone-electrolyte interactions in congestive heart failure: lessons from a 4,000-year-old Sumerian tablet. (1990) (9)
A novel approach to the development of positive inotropic agents for chronic heart failure. (1995) (9)
Effects of carvedilol on cardiovascular hospitalizations in patients with chronic heart failure (1996) (9)
Management of patients with heart failure and angina: do coexistent diseases alter the response to cardiovascular drugs? (1991) (9)
Compelling First-Line Drug and Device Therapies for the Prevention of Sudden Death in Patients With Chronic Heart Failure and a Reduced Ejection Fraction Who Are Candidates for an Implantable Cardioverter-Defibrillator. (2019) (9)
Selective activation of neurohormonal systems in post-infarction left ventricular dysfunction (1991) (9)
Why is the use of digitalis withering? Another reason that we need medical heart failure specialists (2018) (9)
The effect of treatment on survival in congestive heart failure (1992) (9)
Abstract 17948: Reduced Loop Diuretic Use in Patients Taking Sacubitril/Valsartan Compared With Enalapril: The Paradigm-HF Study (2016) (9)
Effectiveness of Medical Therapy for Functional Mitral Regurgitation in Heart Failure With Reduced Ejection Fraction. (2020) (9)
Are nitrates effective in the treatment of chronic heart failure? Antagonist's viewpoint. (1990) (9)
Effect of vasodilator and inotropic drugs on clinical symptoms and long-term survival in chronic congestive heart failure. (1988) (9)
Clinical trials in congestive heart failure: why do studies report conflicting results? (1988) (9)
Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF (2022) (9)
Distinguishing Proportionate and Disproportionate Subtypes in Functional Mitral Regurgitation and Left Ventricular Systolic Dysfunction. (2020) (8)
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction (2022) (8)
Disproportionate secondary mitral regurgitation: myths, misconceptions and clinical implications (2020) (8)
Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction. (2022) (8)
Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure (2022) (8)
Neurohormonal Antagonists Are Preferred to an Implantable Cardioverter-Defibrillator in Preventing Sudden Death in Heart Failure. (2019) (8)
Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study. (2006) (8)
The CABANA Trial: an honourable view. (2018) (8)
Calcium antagonists for congestive heart failure: Evolving concepts in bridge building (1993) (8)
Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age. (2022) (8)
Central hemodynamic effects of dipyridamole in severe heart failure: Comparison with hydralazine (1982) (7)
HEART FAILURE IN THE 1991S : EVOLUTION OF A MAJOR PUBLIC HEALTH PROBLEM INCARDIOVASCULAR MEDICINE (1993) (7)
Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. (2020) (7)
Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in EMPEROR‐Reduced (2022) (7)
Do Most Obese People with Exercise Intolerance and a Normal Ejection Fraction Have Treatable Heart Failure? (2018) (7)
Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM‐HF analysis (2021) (7)
Double Vision: Replicating a Trial Showing a Survival Benefit. (2017) (7)
Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction (2021) (7)
The first dose response to captopril is superior to the pretreatment plasma renin activity in predicting its long-term hemodynamic effects in severe heart failure (1982) (7)
Obesity-Associated Heart Failure as a Theoretical Target for Treatment With Mineralocorticoid Receptor Antagonists (2018) (7)
The Future Treatment of Heart Failure? (2018) (7)
Critical role of the epicardium in mediating cardiac inflammation and fibrosis in patients with type 2 diabetes (2019) (7)
Design and rationale of the EMPEROR trials of, empagliflozin 10 mg once daily, in patients with chronic heart failure with reduced ejection fraction (EMPEROR-Reduced) or preserved ejection fraction (EMPEROR-Preserved) (2019) (7)
Warfarin and antiplatelet therapy study in chronic heart failure (WATCH): Trial design (1999) (7)
Simultaneous Modeling of the Pharmacokinetic and Pharmacodynamic Properties of Enalkiren (Abbott‐64662, A Renin Inhibitor). II: A Dose‐Ranging Study in Patients with Congestive Heart Failure (1993) (7)
Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan (2021) (7)
Diastolic function as a target of therapeutic interventions in chronic heart failure. (1990) (7)
Potential Role of Atrial Myopathy in the Pathogenesis of Stroke in Rheumatoid Arthritis and Psoriasis: A Conceptual Framework and Implications for Prophylaxis (2020) (6)
Prognostic Implications of N-terminal Pro-B Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved. (2022) (6)
Does inotropic therapy shorten survival in patients with severe chronic heart failure (1985) (6)
Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM‐HF (2020) (6)
Potential Interactions When Prescribing SGLT2 Inhibitors and Intravenous Iron in Combination in Heart Failure. (2022) (6)
Importance of assessing changes in ventricular response to atrial fibrillation during evaluation of new heart failure therapies: experience from trials of flosequinan. (1996) (6)
Study design of a mortality trial with intravenous levosimendan (the SURVIVE study) in patients with acutely decompensated heart failure (2004) (6)
Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. (2021) (6)
Efficacy of LCZ696 Persists at Lower Than Target Doses in the PARADIGM-HF Trial (2015) (6)
Effect of Sacubitril/Valsartan Compared with Enalapril, According to Aetiology in Paradigm-HF (2017) (6)
Why Has a Run-In Period Been a Design Element in Most Landmark Clinical Trials? Analysis of the Critical Role of Run-In Periods in Drug Development. (2017) (6)
Comparative hemodynamic effects of low dose and high dose nitroprusside in patients with refractory congestive heart failure (1979) (6)
Global Differences in Heart Failure With Preserved Ejection Fraction (2021) (6)
Does pulmonary vasoconstriction play an important role in patients with primary pulmonary hypertension? A skeptic's view of vasodilator therapy. (1985) (6)
Have we really demonstrated the cardiovascular safety of anti‐hyperglycaemic drugs? Rethinking the concepts of macrovascular and microvascular disease in type 2 diabetes (2018) (6)
Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced (2022) (6)
Racial Differences, Outcomes and Response to Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: PARADIGM-HF (2016) (6)
Proportionate and Disproportionate Functional Mitral Regurgitation (2019) (6)
Quantification of valvular regurgitation before and after medical and surgical therapy by radionuclide angiography (1981) (6)
Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure (2022) (6)
How can sodium–glucose cotransporter 2 inhibitors stimulate erythrocytosis in patients who are iron‐deficient? Implications for understanding iron homeostasis in heart failure (2022) (6)
Inferential characterization of the dose-response relationships of neurohormonal antagonists in chronic heart failure: A novel approach based on large-scale trials with active comparators. (2018) (6)
Impaired systemic venous capacitance: the neglected mechanism in patients with heart failure and a preserved ejection fraction? (2020) (6)
Peak VO2is superior to 6 minute walk for the prediction of survival in patients with heart failure (1996) (6)
Hemoglobin level is associated with adverse outcomes in patients with severe chronic heart failure: results from the COPERNICUS study (2003) (6)
Hemodynamic and clinical effects of combined therapy with verapamil and propranolol in ischemic heart disease (1984) (6)
VESNARINONE FOR HEART FAILURE. AUTHORS' REPLY (1994) (6)
Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: Insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial. (2015) (5)
Comparative Immediate Hemodynamic and Hormonal Effects of Amrinone and Captopril in Patients with Severe Chronic Heart Failure (1986) (5)
Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR‐Reduced (2022) (5)
Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials (2022) (5)
What Have We Learned From Randomized Controlled Trials of Catheter Ablation for Atrial Fibrillation in Patients With Chronic Heart Failure? (2019) (5)
Is there a drug of choice for vasodilator therapy in patients with refractory heart failure? (1980) (5)
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. (2022) (5)
Future large‐scale clinical trials in cardiovascular medicine: challenges and uncertainties (2018) (5)
Does a Target Dose or a Target Heart Rate Matter to Outcomes When Prescribing β-Blockers to Patients With Chronic Heart Failure? (2018) (5)
When Cardiovascular Trials Collide. (2019) (5)
THE ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR (ARNI), SACUBITRIL/VALSARTAN, IMPROVES LEFT VENTRICULAR MYOCARDIAL DEFORMATION IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (PARAMOUNT TRIAL) (2018) (5)
Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial (2022) (5)
Symposium on therapeutic challenges in the management of congestive heart failure. Part I. (1988) (5)
Side effects and treatment initiation barriers of sodium–glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta‐analysis (2022) (5)
Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial (2021) (5)
Questioning the obvious: does dyspnoea really matter in heart failure? (2018) (5)
Potassium binders for patients with heart failure? The real enlightenment of the DIAMOND trial (2022) (5)
IMPACT OF INTRODUCTION OF PULMONARY ARTERY PRESSURE MONITORING FOR HEART FAILURE MANAGEMENT: LONGITUDINAL RESULTS FROM THE CHAMPION TRIAL (2014) (5)
The editor's roundtable: nonsteroidal antiinflammatory drugs and cardiovascular risk. (2008) (5)
How have millions of people with heart failure benefited from our research over the last 10–15 years? The sounds of dead silence (2017) (5)
Who Should Deliver Medical Therapy for Patients With Chronic Heart Failure? An Immediate Call for Action to Implement a Community-Based Collaborative Solution. (2017) (5)
Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes? (2018) (5)
Lymphocyte G proteins reflect response to treatment in congestive heart failure. (1995) (4)
Absence of an Ideal Observer II: The Agonizing Search for Experts Without a Conflict of Interest. (2017) (4)
High diuretic doses are associated with sudden death in patients with advanced heart failure: The PRAISE trial (1998) (4)
SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism (2023) (4)
Role of Payers in the Development of Cardiovascular Therapeutics: Misalignment Between Approval and Reimbursement. (2017) (4)
The Parable of Schrödinger's Cat and the Illusion of Statistical Significance in Clinical Trials. (2019) (4)
Association of chronic kidney disease with abnormal cardiac structure and function in a HFpEF population : the PARAMOUNT study (2013) (4)
Controlled-release carvedilol: a concluding perspective. (2006) (4)
Nonarrhythmic Sudden Cardiac Death in Chronic Heart Failure-A Preventable Event? (2019) (4)
Pitfalls in Using Estimated Glomerular Filtration Rate Slope as a Surrogate for the Effect of Drugs on the Risk of Serious Adverse Renal Outcomes in Clinical Trials of Patients With Heart Failure (2021) (4)
Levosimendan Provides Rapid and Sustained Relief in Patient Global Assessment of Acutely Decompensated Heart Failure: The REVIVE II Study (2006) (4)
Accelerated and personalized therapy for heart failure with reduced ejection fraction. (2022) (4)
Higher mortality rate in patients with heart failure who are taking commonly prescribed antidiabetic medications and achieve recommended levels of glycaemic control (2018) (4)
Does Neprilysin Inhibition Potentiate or Minimize the Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Heart Failure? (2018) (4)
Corrigendum: Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis (2013) (4)
Ten lessons from the EMPEROR‐Reduced trial (2020) (4)
IMPACT OF CARDIOVASCULAR AND NON-CARDIOVASCULAR HOSPITALIZATION ON QUALITY OF LIFE IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION (2020) (4)
Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials. (2021) (4)
Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. (2022) (3)
P3373Better health-related quality of life in patients treated with sacubitril/valsartan compared with enalapril, irrespective of NYHA class: Analysis of EQ-5D in PARADIGM-HF (2017) (3)
Do the Favorable Effects of Digoxin and SGLT2 Inhibitors Really Differ in Patients with Heart Failure and a Reduced Ejection Fraction? A Provocative Side-by-Side Examination of Trial Outcomes (2022) (3)
Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and In ﬂ ammation on the Myocardium (2018) (3)
901-74 Delayed and Incomplete Reversal of Impaired Metabolic Vasodilation in Patients with Heart Failure During Long-term Circulatory Support with a Left Ventricular Assist Device (1995) (3)
Levosimendan Reduces Length of Initial Hospital Stay: The REVIVE II Study (2006) (3)
Comparison of Angioedema in Heart Failure Patients Treated with Sacubitril/Valsartan or Enalapril in the PARADIGM-HF Study (2016) (3)
Empagliflozin in Black Versus White Patients with Heart Failure: Analysis of EMPEROR-Pooled. (2022) (3)
842-2 Hemoglobin level is associated with mortality and hospitalization in patients with severe chronic heart failure: Results from the COPERNICUS study (2004) (3)
Natriuretic peptide‐based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON‐HF (2022) (3)
c.,,on Officia 1. urnalof theC,merica nHeartrAssociation, Inc. FEATURES Neurohormonal interactions andadaptations in congestive heart failure (1988) (3)
Abstract 17986: Is There Really an “Obesity Paradox” in Heart Failure? An Analysis of PARADIGM-HF (2016) (3)
Tetralogy of Fallow: Four Trials and Tribulations. (2017) (3)
965-51 Daily Coronary Microembolization in Awake Dogs Leads to Heart Failure (1995) (3)
Natriuretic Peptide Plasma Concentrations and Risk of Cardiovascular Versus Non-Cardiovascular Events in Heart Failure with Reduced Ejection Fraction Insights from the PARADIGM-HF and ATMOSPHERE Trials. (2021) (3)
Heart rate, heart rhythm and prognostic benefits of beta-blockers in heart failure: individual patient-data meta-analysis (2017) (3)
Is the Dose Used the Dose Tested (1994) (3)
Detrimental effects ofverapamil inpatientswith primary pulmonary hypertension (1984) (3)
Early Worsening of Renal Function After Treatment with Antihyperglycemic Drugs: A Consistent Finding in Large-Scale Trials. (2017) (3)
Comparative hemodynamic effects of high dose prazosin and nitroprusside in refractory heart failure (1978) (3)
Correction Impaired systolic function by strain imaging in heart failure with preserved ejection fraction (vol 63, pg 447, 2014) (2014) (3)
Diastolic heart failure. (2004) (3)
Risk of provoking myocardial ischemic events during initiation of vasodilator therapy for chronic heart failure: Evaluation of 40 consecutive patients with ischemic cardiomyopathies (1980) (3)
Perspective* Do b-Blockers Prolong Survival in Heart Failure Only by Inhibiting the b 1 -Receptor? A Perspective on the Results of the COMET Trial (2003) (3)
Influence of study discontinuation during the run‐in period on the estimated efficacy of sacubitril/valsartan in the PARAGON‐HF trial (2021) (3)
Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR‐Preserved trial (2022) (3)
Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction. (2023) (3)
Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation (2022) (3)
Circulation Editors and Editorial Board. (2018) (3)
Nonadrenergic Hormonal Alterations in Congestive Heart Failure (1994) (3)
Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced (2022) (3)
Contrasting effects on the risk of macrovascular and microvascular events of antihyperglycemic drugs that enhance sodium excretion and lower blood pressure (2018) (3)
Effect of carvedilol on major clinical events in patients with severe heart failure and an extremely depressed ejection fraction: results of the COPERNICUS study (2002) (3)
Prognostic Implications of Achieving an N-Terminal Pro-B-Type Natriuretic Peptide Level <1000 pg/ml in Patients With Heart Failure: Data From PARADIGM-HF (2015) (3)
LOW URINARY CGMP/BNP RATIO IS ASSOCIATED WITH WORSE OUTCOMES IN HEART FAILURE BUT IS INCREASED BY TREATMENT WITH SACUBITRIL/VALSARTAN: AN ANALYSIS OF PARADIGM-HF (2017) (2)
Activation of vasoconstrictor mechanisms during vasodilator therapy: A factor modifying drug response in heart failure (1980) (2)
A Compelling Case for Less Aggressive Arrhythmia Management in Patients With Chronic Heart Failure and Long-Standing Atrial Fibrillation. (2019) (2)
Panel discussion I: Evaluation and management of chronic heart failure (1993) (2)
The Role of Vasodilator Therapy in the Treatment of Severe Chronic Heart Failure (2012) (2)
A Report from the Late Breaking Clinical Trials Session of the Annual Scientific Meeting of the Heart Failure Society of America (2002) (2)
Six lessons learned from the use of SGLT2 inhibitors in patients with heart failure (2022) (2)
744-5 Ischemic Heart Failure is Associated with Reduced Blood Flow Reserve in Non-embolized Arteries in Awake Dogs (1995) (2)
Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial (2022) (2)
Incidence, Predictors, and Outcomes Associated with Hypotensive Episodes among Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (2016) (2)
A COST-EFFECTIVENESS ANALYSIS IN THE US OF LCZ696 (SACUBITRIL/VALSARTAN) VERSUS RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITION FOR HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION (2016) (2)
Severe Chronic Heart Failure (2005) (2)
Nitric oxide (NO) is the mediator responsible for physical training-normalized vasodilation of epicardial coronary artery during development of heart failure (HF) (1996) (2)
Usefulness of echocardiographically determined left ventricular volume as a non-invasive predictor of hydralazine response in heart failure (1979) (2)
Does digitalis influence the response to beta-blockade in patients with severe chronic heart failure? Results of the COPERNICUS study (2002) (2)
Concerns About the Use of Metformin as a First-Line Agent to Slow the Progression of Chronic Kidney Disease in Diabetes. (2020) (2)
Is Long-Standing Atrial Fibrillation a Biomarker of or Contributor to the Symptoms or Progression of Chronic Heart Failure? (2019) (2)
Is the Popularity of Dipeptidyl-Peptidase-4 Inhibitors Justified? Insights From Mechanistic Studies and Clinical Trials. (2018) (2)
Do positive inotropic agents adversely affect the survival of patients with chronic congestive heart failure? II. Protagonist's viewpoint. (1988) (2)
Identification of risk factors predisposing to the development of functional renal insufficiency during treatment with converting-enzyme inhibitors in chronic heart failure. (1989) (2)
The Absence of an Ideal Observer: Why Some Clinical Trials May Not Be What We Think They Are. (2017) (2)
b -Blockade in Heart Failure Basic Concepts and Clinical Results (1998) (2)
Renal effects of lcz696 in patients with heart failure and preserved ejection fraction: results from paramount (2013) (2)
Heightened risk of intensive rate control in patients with atrial fibrillation who are obese or have type 2 diabetes: A critical review and re‐evaluation (2019) (2)
Circadian rhythm and sudden death in heart failure: Results from praise (1996) (2)
Key issues in trial design for ventricular assist devices: a position statement of the Heart Failure Society of America. (2004) (2)
Oral levosimendan, a novel myofilament calcium sensitizer, is an effective substitute for intravenous inotropic therapy in class IV inotrope-dependent heart failure patients (1999) (2)
The ischaemic heart: β-blockade or calcium channel blockade? (1993) (2)
How do vasodilators improve cardiac performance in chronic heart failure? Insights gained from two-dimensional color flow Doppler echocardiography (1990) (2)
The current status of angiotensin converting enzyme inhibitors in the management of patients with chronic heart failure. (1989) (2)
Risks of Intensive Treatment of Long-Standing Atrial Fibrillation in Patients With Chronic Heart Failure With a Reduced or Preserved Ejection Fraction. (2019) (2)
INFLUENCE OF AGE ON EFFICACY AND SAFETY OF SACUBITRIL/VALSARTAN IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (2020) (2)
Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. (2023) (2)
CONSISTENT BENEFIT OF SACUBITRIL/VALSARTAN OVER ENALAPRIL, IRRESPECTIVE OF BACKGROUND THERAPY IN PARADIGM-HF (2016) (2)
Cardiac failure: editorial overview: Advances in the pathogenesis and treatment of heart failure (1989) (2)
Deleterious hemodynamic and clinical responses to hydralazine in patients with severe secondary pulmonary hypertension (1982) (2)
Methodological and Clinical Heterogeneity and Extraction Errors in Meta‐Analyses of Catheter Ablation for Atrial Fibrillation in Heart Failure (2019) (2)
Alleviation of functional iron deficiency by SGLT2 inhibition in patients with type 2 diabetes (2022) (2)
Health‐related quality of life outcomes in PARAGON‐HF (2022) (2)
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial. (2022) (2)
Verapamil therapy for the management of hypertrophic cardiomyopathy (1984) (2)
INFLUENCE OF SACUBITRIL/VALSARTAN ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES AND HEART FAILURE WITH REDUCED EJECTION FRACTION (2017) (2)
Effect of Extended-Release Niacin on Carotid Intima Media Thickness, Reactive Hyperemia, and Endothelial Progenitor Cell Mobilization: Insights From the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial. (2015) (2)
Does digitalis work in chronic heart failure? The end of a 200-year-old controversy (2004) (1)
758-1 Vasodilator Capacity of Coronary Resistance Vessels is Maintained by Chronic Exercise Training During Development of Heart Failure in Awake Dogs (1995) (1)
How to Demonstrate the Efficacy of a New Drug for the Treatment of Chronic Heart Failure (1990) (1)
Can acute hemodynamic studies in heart failure be used to predict the optimal dose of a new drug during long-term therapy? (1991) (1)
Let Us Not Forget the Long-term Safety Concerns of Sacubitril/Valsartan-Reply. (2017) (1)
Drugs that slow the progression of diabetic kidney disease: are renoprotective effects attenuated in heart failure? (2023) (1)
Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial (2022) (1)
Converting-Enzyme Inhibition in the Management of Patients with Severe Chronic Congestive Heart Failure (1986) (1)
Abstract 17955: Reduction in 30-day Rehospitalization After Discharge From a Heart Failure Admission in Patients Receiving LCZ696 versus Enalapril: PARADIGM-HF (2015) (1)
Erratum to “Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency” [Eur J Heart Fail 2016;18:482‐489] (2016) (1)
The role of nitric oxide (NO) in the beneficial effects of chronic exercise training on heart failure in awake dogs (1996) (1)
Glucagon‐like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta‐analysis of randomized placebo‐controlled outcome trials (2023) (1)
Effect of gender on the outcome of patients with severe heart failure treated with carvedliol: results of the COPERNICUS study (2002) (1)
IMPACT OF BODY MASS INDEX ON THE ACCURACY OF NT-PROBNP AND BNP FOR PREDICTING OUTCOMES IN PATIENTS WITH CHRONIC HEART FAILURE AND REDUCED EJECTION FRACTION: INSIGHTS FROM THE PARADIGM-HF STUDY (2016) (1)
Are healthcare systems now ready to adopt sacubitril/valsartan as the preferred approach to inhibiting the renin-angiotensin system in chronic heart failure? The culmination of a 20-year journey. (2019) (1)
Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials (2023) (1)
Abstract 17434: Insulin-Like Growth Factor Binding Protein-7 as a Biomarker of Diastolic Dysfunction: Results From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction (PARAMOUNT) Study (2017) (1)
248Effect of sacubitril/valsartan on plasma biomarkers that reflect extracellular matrix regulatory mechanisms and collagen synthesis in patients with heart failure and reduced ejection fraction (2017) (1)
Abstract 20000: Efficacy and Safety of Sacubitril/Valsartan in Patients in NYHA Functional Class IV. An Analysis Of PARADIGM-HF (2016) (1)
THE EFFICACY OF THE ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR, LCZ696, IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION IS INDEPENDENT OF BLOOD PRESSURE LOWERING (2014) (1)
Electrophysiological interventions in the treatment of chronic heart failure: a comparison of the strength of evidence supporting cardiac resynchronization for electrical conduction delay and catheter ablation for atrial fibrillation (2019) (1)
Seferovic, J. P. et al. (2017) Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes (2017) (1)
Risk of Adverse Events with Liraglutide in HFrEF: A post-hoc analysis of the FIGHT trial. (2022) (1)
Carvedilol reduced mortality and hospitalization in chronic heart failure (1996) (1)
Do amiodarone and dronedarone prevent thrombo-embolic stroke by treating the atrial myopathy of patients with atrial fibrillation? A provocative hypothesis. (2020) (1)
981-53 Impaired Ventilatory Adaptations to Submaximal Exercise in Patients with Chronic Heart Failure (1995) (1)
Association of gender with abnormal cardiovascular structure and function in heart failure with preserved ejection fraction : the PARAMOUNT study (2013) (1)
Plasma N-terminal pro-BNP predicts the occurrence of major clinical events in severe chronic heart failure: results of a substudy of the COPERNICUS trial (2002) (1)
948-49 Prognostic Importance of the Oxidation Products of Catecholamines (Adrenochromes) in Patients with Heart Failure (1995) (1)
PROGNOSTIC IMPLICATIONS OF BASELINE AND FOLLOW-UP CARDIOVASCULAR PHYSICAL EXAMS IN A CONTEMPORARY TRIAL OF PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION: PARADIGM-HF (2019) (1)
Symptom relief does not reflect reduced clinical events in heart failure: a report from the ATLAS study (1999) (1)
Dosing of losartan in men vs. women with HFrEF: the HEAAL trial. (2021) (1)
821-1 Should beta-blockers be used before angiotensin converting enzyme inhibitors in patients with chronic heart failure? Meta-analysis of the prognostic benefit conferred by beta-blockers in patients not receiving ACE inhibitors (2004) (1)
Renin inhibition (but not plasma renin activity) predicts the response to converting-enzyme inhibitors in chronic heart failure (1990) (1)
Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients with Heart Failure. (2023) (1)
Prognosis determination in heart failure. Discussion (2001) (1)
Should recommendations for clinical use be restricted to patients who were enrolled in a pivotal clinical trial? (2017) (1)
Calcium Channel Antagonists in Cardiovascular Disease: Focus on Verapamil (1984) (1)
LEFT VENTRICULAR DYSSYNCHRONY IS ASSOCIATED WITH WORSE DIASTOLIC DYSFUNCTION IN PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION (2013) (1)
Does the degree of interference with the renin-angiotensin system influence the response to B-blockade in chronic heart failure? Results of the COPERNICUS study (2002) (1)
Is Any Patient with Chronic Heart Failure Receiving the Right Dose of the Right Beta-Blocker in Primary Care? (2019) (1)
Abstract 19363: Prevention of Progressive Worsening of Heart Failure Over Time With The Angiotensin-receptor Neprilysin Inhibitor Sacubitril/valsartan (lcz696) (2015) (1)
Kidney function assessment and endpoint ascertainment in clinical trials. (2021) (1)
Design of Phase II trials in congestive heart failure (2000) (1)
channel blockade in man Hemodynamic consequences of combined beta-adrenergic and slow calcium (2011) (0)
Defining Secondary Mitral Regurgitation: Evidence that the 2017 Updated Guidelines Got it Right (2019) (0)
Selection of Vasodilator Drugs for Patients with Severe Chronic Heart Failure: An Approach Based on a New Classification (1982) (0)
Pressure overload induction of C-fosexpression in adult rat hearts is not blocked by angiotensin II type 1 receptor antagonist in vivo (1996) (0)
DECLINE IN ESTIMATED GLOMERULAR FILTRATION RATE FOLLOWING SACUBITRIL/VALSARTAN INITIATION IN PATIENTS WITH HEART FAILURE: INSIGHTS FROM PARAGON-HF AND PARADIGM-HF (2023) (0)
Effect Of Empagliflozin On Major Heart Failure Outcomes, Renal Function And Quality Of Life In Patients With Heart Failure With A Reduced Ejection Fraction, With And Without Sacubitril/valsartan (2020) (0)
Panel discussion II: Directions for future research (1993) (0)
Physician global assessment of heart failure patients: comparison with patient global assessment and quality of life scores in the ATTACH trial (2004) (0)
What causes exertional dyspnoea in patients with atrial fibrillation? Implications for catheter ablation in patients with heart failure (2021) (0)
Why Are Physicians So Confused about Acute Heart Failure?. Reply. (2019) (0)
Routine Measurement of Natriuretic Peptide to Guide the Diagnosis and Management of Chronic Heart Failure: Response (2004) (0)
Implications of the 2021 CKD-EPI cystatin C/creatinine eGFR equation for eligibility for therapy in HFrEF: insights from PARADIGM-HF (2022) (0)
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Preserved Trial. (2023) (0)
Abstract 19644: Analysis of Recurrent (Including First and Repeat) Primary Endpoint Events (Composite of Heart Failure Hospitalizations and Cardiovascular Death) in PARADIGM-HF (2016) (0)
SacubitrilValsartan in Heart Failure (2017) (0)
Utility of Prazosin in the Management of Patients with Severe Chronic Congestive Heart Failure (1986) (0)
THE IMPORTANCE OF BLOOD UREA NITROGEN TO CREATININE RATIO IN PATIENTS WITH HFPEF AND HFREF (2023) (0)
Alkaline phosphatase and bilirubin combined are a powerful predictor of outcome in patients with heart failure and reduced ejection fraction: an analysis of the ATMOSPHERE and PARADIGM-HF trials (2022) (0)
Adverse Hemodynamic and Clinical Responses to Long-term Inotropic Therapy in Patients with Severe Chronic Congestive Heart Failure (1986) (0)
History of stroke in patients with heart failure: prevalence, baseline characteristics and clinical outcomes (2022) (0)
Abstract 17912: Health-related Quality of Life Outcomes in PARADIGM-HF (2015) (0)
Abstract 16903: Circulating Growth Differentiation Factor 15 (GDF-15) in Patients With Heart Failure With Reduced Ejection Fraction: Insights From PARADIGM-HF (2017) (0)
University of Birmingham Impact of renal impairment on beta-blocker efficacy in patients with heart failure (2020) (0)
RED CELL DISTRIBUTION WIDTH IS AN INDEPENDENT PREDICTOR OF OUTCOMES IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: AN ANALYSIS OF THE PARAGON-HF TRIAL (2023) (0)
Pitfalls in the Design and Evaluation of Clinical Trials of Intravenously Administered Cardiovascular Drugs (1989) (0)
LONG-TERM DIGOXIN THERAPY. AUTHORS' REPLY (1995) (0)
Prevalent and incident anaemia in PARADIGM-HF and effect of sacubitril/valsartan (2022) (0)
Treatment Effects of Sacubitril/Valsartan Compared With Valsartan in Patients with Recent Hospitalization. (2021) (0)
Stroke in patients with heart failure and reduced ejection fraction without atrial fibrillation: external validation of a risk model (2022) (0)
Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor- (cid:1) , in Patients With Moderate-to-Severe Heart Failure Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial Clinical Investigation and Rep (2003) (0)
Pathophysiology: Discussion II (1993) (0)
Coexistent heart failure and angina require different therapy than either entity alone (1991) (0)
Effect of age and sex on efficacy and tolerability of beta blockers in patients with heart failure with reduced ejection fraction (2016) (0)
Differences in the responses to captopril and nitroprusside in severe heart failure indicate that captopril has actions independent of its vasodilator effects (1982) (0)
Myocardial infarction: prevention of acute and chronic dilatation (1989) (0)
WIRKUNG VON CAPTOPRIL AUF MORTALITAT UND MORBIDITAT BEI PATIENTEN MIT LINKSVENTRIKULARER DYSFUNKTION NACH MYOKARDINFARKT. ERGEBNISSE DER 'SURVIVAL-AND-VENTRICULAR-ENLARGEMENT'-STUDIE (1992) (0)
Combining Iron Supplements With SGLT2 Inhibitor-Stimulated Erythropoiesis in Heart Failure: Should We Be Worried About Thromboembolic Events? (2022) (0)
Response by Packer to Letter Regarding Article, "Activation and Inhibition of Sodium-Hydrogen Exchange Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure". (2018) (0)
NATRIURETIC PEPTIDES AS PREDICTIVE BIOMARKERS OF TREATMENT RESPONSE IN CLINICAL TRIALS OF HEART FAILURE (2018) (0)
Are Placebo-Controlled Trials Necessary in the Evaluation of New Therapeutic Agents in Severe Chronic Heart Failure? (1987) (0)
Sacubitril/Valsartan Reduces Serum Uric Acid Level, an Independent Predictor of Adverse Outcomes in HFrEF: Results From PARADIGM-HF (2016) (0)
EFFECT OF SACUBITRIL/VALSARTAN ON SERUM LIPIDS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: PARAGON-HF (2021) (0)
Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial (2023) (0)
Prediction of maximal oxygen consumption by six minute walk testing in patients with congestive heart failure (1996) (0)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction. Reply. (2022) (0)
Withdrawal of digoxin after treatment of chronic heart failure led to clinical deterioration and worsening heart failure (1994) (0)
EFFECT OF EXTENDED-RELEASE NIACIN ON REACTIVE HYPEREMIA PERIPHERAL ARTERIAL TONOMETRY AND ENDOTHELIAL PROGENITOR CELL MOBILIZATION: INSIGHTS FROM THE ATHEROSCLEROSIS LESION PROGRESSION INTERVENTION USING NIACIN EXTENDED RELEASE IN SAPHENOUS VEIN GRAFTS (ALPINE-SVG) PILOT TRIAL (2015) (0)
Response by Packer to Letter Regarding Article, "Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure: A 20-Year Perspective". (2017) (0)
Assessment of clinical outcome in heart failure: Discussion IX (1993) (0)
SGLT2 inhibitor treatment lowers serum uric acid in patients with HFrEF - Lessons from clinical trials. (2022) (0)
EFFECT OF PRIMARY PREVENTION IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR THERAPY ON MORTALITY AND SUDDEN CARDIAC DEATH IN HEART FAILURE TREATED WITH SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS: AN ANALYSIS FROM THE EMPEROR-REDUCED TRIAL (2023) (0)
Do all heart failure patients benefit from high dose Lisinopril? Results from the ATLAS study (2000) (0)
Risk of heart failure in diabetic patients receiving sulfonylureas: reply (2018) (0)
SUPPLEMENTAL MATERIAL Factors Associated with Noncompletion During the Run ‐ in Period Prior to Randomization and the Efficacy of LCZ 696 in the PARADIGM ‐ HF Trial (2016) (0)
EFFECTS OF SACUBITRIL/VALSARTAN VERSUS VALSARTAN ON RENAL FUNCTION IN PATIENTS WITH TYPE 2 DIABETES AND HEART FAILURE WITH PRESERVED EJECTION FRACTION: PARAGON-HF (2022) (0)
Data monitoring in the Prospective Randomized Milrinone Survival Evaluation: Dealing with an agonizing trend (2006) (0)
Prognostic implications of NYHA class and NT-proBNP levels in mild heart failure: a PARADIGM-HF analysis (2022) (0)
RECENCY OF HEART FAILURE HOSPITALIZATION AND THE EFFECT OF EMPAGLIFLOZIN: AN EMPEROR-POOLED ANALYSIS (2023) (0)
Abstract 11098: Abnormalities of Left Ventricular Systolic Function in Heart Failure with Preserved Ejection Fraction (2012) (0)
Side effects and treatment initiation barriers of SGLT2 inhibitors in heart failure: A systematic review and meta-analysis. (2022) (0)
Vasodilator Therapy for Primary Pulmonary Hypertension (2020) (0)
The First Dedicated Comprehensive Heart Failure Program in the US: the Division of Circulatory Physiology at Columbia Presbyterian (1992-2004). (2023) (0)
P2630Incidence and prognostic impact of new-onset left bundle branch block in patients with heart failure and reduced ejection fraction (2019) (0)
Abstract 17063: Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure (2020) (0)
Health Status Across Major Subgroup of Patients with Heart Failure and Preserved Ejection Fraction. (2023) (0)
Abstract 17374: Reduced Risk of Hyperkalemia in Heart Failure Patients Treated With an MRA and Sacubitril/Valsartan Compared With Enalapril: The PARADIGM-HF Trial (2016) (0)
Diuretics and Exercise: Discussion VIII (1993) (0)
Efficacy and safety of carvedilol in patients with severe chronic heart failure and low systolic blood pressure: results of the COPERNICUS study (2002) (0)
INDICATIONS FOR LV ANEURYSMECTOMY / Cohen (2005) (0)
1163-119 Changes of inflammatory cytokines and uric acid in patients with severe chronic heart failure: A COPERNICUS substudy (2004) (0)
Effect of digoxin withdrawal in patients with chronic heart failure receiving carvedilol (2004) (0)
757-5 Hemodynamic Effects of Synthetic Human Brain Natriuretic Peptide Infusion in Patients with Severe Congestive Heart Failure: A Placebo-controlled, Crossover Trial (1995) (0)
Abstract 17176: Burden and Prognostic Importance of Heart Failure Signs and Symptoms - Differences in Heart Failure With Preserved versus Reduced Ejection Fraction (2020) (0)
A comprehensive study of the incremental prognostic value of novel biomarkers in PARADIGM-HF (Bio-PREDICT-HF) (2022) (0)
Milton Packer, MD, Director, Center for Biostatistics and Clinical Science at UT Southwestern (2004) (0)
Dispelling the myth: incorporating beta-blockers into practice guidelines. (2000) (0)
Sex bias in the management of coronary artery disease (1990) (0)
Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium-glucose cotransporter 2 inhibitors. (2023) (0)
Clinical Decompensation in Stable Patients With Chronic Heart Failure Utility of Impedance Cardiography for the Identification of Short-Term Risk of (2006) (0)
Calcium channel blockers in chronic heart failure. The risks of "physiologically (2005) (0)
Baseline Characteristics of the Patients in the Two Treatment Groups * Placebo (2005) (0)
Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause (2022) (0)
Monoclonal Antibody to Tumor Necrosis Factor-Randomized , Double-Blind , Placebo-Controlled , Pilot Trial of Infliximab , a Chimeric (2003) (0)
Impact of multimorbidity on mortality in HFrEF: Which comorbidities matter most? - An analysis of PARADIGM-HF and ATMOSPHERE. (2023) (0)
Increased risk of heart failure hospitalization with GLP-1 receptor agonists in patients with reduced ejection fraction: a meta-analysis of the EXSCEL and FIGHT trials. (2023) (0)
Can We Expect Vasodilator Therapy to Prolong Life in Patients with Congestive Heart Failure? (1987) (0)
704-6 Chronic Exercise Training Restores Endothelium-mediated Control of Epicardial Coronary Artery During Development of Heart Failure in Awake Dogs (1995) (0)
359 After-Shift Reflections by Emergency Physicians (2012) (0)
Therapeutic challenges in the management of congestive heart failure. II (1988) (0)
Management of Primary Pulmonary Hypertension (1988) (0)
Use and abuse of clinical trials. Is the dose used the dose tested? (1994) (0)
Influence of Diabetes Mellitus on Cardiac Structure and Function and Response to Therapy with LCZ696 in Heart Failure with Preserved Ejection Fraction (2014) (0)
ORAL ABSTRACT SESSION: CLINICAL (2013) (0)
The diverging role of epicardial adipose tissue in heart failure with reduced and preserved ejection fraction: not all fat is created equal (2021) (0)
hypertension . patients with primary pulmonary Detrimental effects of verapamil in (0)
The Effect of Sacubitril/Valsartan on Left Ventricular Myocardial Deformation in Heart Failure with Preserved Ejection Fraction (PARAMOUNT trial). (2023) (0)
Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin: An EMPEROR-Pooled Analysis. (2023) (0)
Randomized crossover comparison of the hemodynamic of three type I antiarrhythmic in heart failure (1990) (0)
University of Groningen Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure Beta-Blockers Heart Failure (0)
Arachidonic acid-induced dilation of epicardial coronary artery is maintained in awake dogs with chronic exercise training plus rapid cardiac pacing (1996) (0)
An individualized prediction of heart failure survival – derivation from PRAISE1 and validation in ELITE2 (2004) (0)
Clinical Investigations Regional Differences in the Characteristics and Treatment of Patients Participating in an International Heart Failure Trial (1998) (0)
Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation. (2023) (0)
Lack of a significant triphasic response to captopril therapy during serial hemodynamic evaluation of patients with severe heart failure (1982) (0)
Dosing of iron supplementation for iron‐deficient patients with heart failure: should we prefer more intensive or less intensive repletion targets? (2023) (0)
Sodium–glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction – lessons from clinical trials. Letter regarding the article ‘Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF (2022) (0)
Increases in Fibroblast Growth Factor 23 During Treatment With Ferric Carboxymaltose: Potential Adverse Effects on the Heart and Kidneys. (2022) (0)
Abstract 17751: Predicting Cardiovascular Death in Patients With Heart Failure and Reduced Ejection Fraction: The PARADIGM-HF/ATMOSPHERE Prognostic Model (2016) (0)
RELATIVE APICAL SPARING PATTERN IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (THE PARAGON-HF AND TOPCAT TRIALS) (2021) (0)
Effect of carvedilol on major cardiovascular events in post-infarction patients treated with angiotensin converting enzyme inhibitors: Further analysis of the capricorn trial (2003) (0)
Circulating levels of tumor necrosis factor are elevated in end-stage congestive heart failure: A possible cause of cardiac cachexia (1990) (0)
Potential mechanisms underlying differences in the effect of incretin-based antidiabetic drugs on the risk of major atherosclerotic ischemic events. (2018) (0)
Link Between Synovial and Myocardial Inflammation: Conceptual Framework to Explain the Pathogenesis of Heart Failure with Preserved Ejection Fraction in Patients with Systemic Rheumatic Diseases (2019) (0)
Sacubitril/Valsartan Associated with Lower Declines in Health-Related Quality of Life Compared with Enalapril in Patients with Heart Failure Hospitalization (2016) (0)
PARADIGM-HF: Novel Drug Reduced Outcomes, Improved Symptoms Better Than ACE Inhibition (2014) (0)
ELEVATED HIGH SENSITIVITY TROPONIN IS ASSOCIATED WITH POORER OUTCOMES IN PATIENTS WITH HEART FAILURE AND REDUCED BY SACUBITRIL/VALSARTAN (2016) (0)
Pathophysiological Mechanisms Underlying the Effects of /3-Adrenergic Agonists and Antagonists (2005) (0)
P5300Prognostic implications of baseline and change from baseline values of plasma biomarkers that reflect extracellular matrix regulatory mechanisms and collagen synthesis in patients with heart failure (2017) (0)
PART IV: ASSESSMENT OF CLINICAL OUTCOME IN HEART FAILURE (2016) (0)
Safety of amlodipine in diabetic patients with advanced congestive heart failure: Results of the PRAISE trial (1998) (0)
Interaction of Natriuretic Peptide Levels and Ejection Fraction on Outcomes with Dapagliflozin and Empagliflozin in Heart Failure. (2023) (0)
MINI-FOCUS ISSUE: HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF) (0)
Abstract 2744: Sex Differences in Heart Failure with Systolic Dysfunction: A Pooled Analysis of Five Randomized Control Trials (2006) (0)
Erratum: Impaired systolic function by strain imaging in heart failure with preserved ejection fraction ( Journal of the American College of Cardiology (2014) 63 (447-456)) (2014) (0)
The Authors Reply. (2020) (0)
HEART-FAILURE - DISCUSSION (1986) (0)
EFFECT OF SACUBITRIL/VALSARTAN VS. ENALAPRIL ON CHANGES IN BACKGROUND MEDICAL THERAPY OVER TIME IN THE PARADIGM-HF TRIAL (2020) (0)
Effect of Long-Term Digoxin Therapy ou Autonomic Function in Patients With Chronic Heart Failure (2016) (0)
Association between Baseline, and Changes in, Health-Related Quality of Life and Death and HF Hospitalization in PARADIGM-HF (2016) (0)
Empagliflozin in Heart Failure. Reply. (2021) (0)
Heart Failure with Preserved Ejection Fraction (2020) (0)
Beth Levine In Memoriam. (2020) (0)
Association of heart rate with heart failure outcomes and the effects of empagliflozin in patients with preserved ejection fraction – EMPEROR-Preserved trial (2022) (0)
0.050). The relative and absolute bene fi ts of sacubitril/valsartan compared with valsartan alone in heart failure with preserved ejection fraction appear to be ampli fi ed when initiated in the high-risk window after hospitalization and warrants prospe (2020) (0)
Reply: does speckle tracking really improve diagnosis and risk stratification in patients with HF with normal EF? (2014) (0)
namic changes that mimic a vasodilator drug response in patients with severe chronic heart failure after right heart catheterization and suggest guidelines for the design of future studies (2005) (0)
Metabolic causes and hemodynamic consequences of chronic unexplained anemia in heart failure (1991) (0)
Cardiac Imaging Impaired Systolic Function by Strain Imaging in Heart Failure With Preserved Ejection Fraction (2014) (0)
Clinical TrialsControlled-Release Carvedilol in Heart Failure and Post-MI LVD: Pharmacokinetics, Pharmacodynamics and Safety (2006) (0)
PARADIGM-HF: Rationale and Design (2014) (0)
Cardiovascular and Kidney Outcomes with Empagliflozin in Heart Failure (2021) (0)
Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial. (2023) (0)
A Reclassification of Heart Failure Based on Recognition of Heart Failure With Normal to Supranormal Ejection Fraction, a Clinically Common Form of Cardiac Contracture, With Distinctive Pathophysiological and Therapeutic Features. (2023) (0)
McMurray, J. J. V. et al. (2014) Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM- (2014) (0)
Aptamer Proteomics for Biomarker Discovery in Heart Failure with Reduced Ejection Fraction (2022) (0)
Is the erythrocyte sedimentation rate a useful marker of the response to therapy in heart failure? A re-evaluation after 50 years (1991) (0)
The Reply. (2018) (0)
Therapeutic Implications-~ ~ ~ in i Abnormalities of Diastolic Function as a Potential Cause of Exercise Intolerance in Chronic Heart Failure (2005) (0)
Response by Dr Packer to the Letter of Dr Blankfield (2018) (0)
Corrigendum to: Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled (2022) (0)
Prognostic implications of baseline and change from baseline values of plasma biomarkers that reflect extracellular matrix regulatory mechanisms and collagen synthesis in patients with heart failure (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Milton Packer?

Milton Packer is affiliated with the following schools:

Milton Packer's Academic­Influence.com Rankings

Why Is Milton Packer Influential?

Milton Packer's Published Works

Published Works

What Schools Are Affiliated With Milton Packer?

Milton Packer's AcademicInfluence.com Rankings